{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein+Control&page=78",
    "query": {
      "intervention": "Protein Control",
      "page": 78
    },
    "page_size": 10
  },
  "pagination": {
    "page": 78,
    "page_size": 10,
    "total_count": 3500,
    "total_pages": 350,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein+Control&page=79&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein+Control&page=77&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-07T19:38:42.464Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02688933",
      "title": "A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "HOE901-U300 (Insulin Glargine 300 U/ml)",
          "type": "DRUG"
        },
        {
          "name": "Lantus (Insulin Glargine 100 U/ml)",
          "type": "DRUG"
        },
        {
          "name": "Mandated back ground therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 638,
      "start_date": "2016-05-05",
      "completion_date": "2017-06-19",
      "has_results": true,
      "last_update_posted_date": "2022-03-28",
      "last_synced_at": "2026-11-07T19:38:42.464Z",
      "location_count": 99,
      "location_summary": "Little Rock, Arkansas • Concord, California • Escondido, California + 80 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02688933"
    },
    {
      "nct_id": "NCT00004978",
      "title": "An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Recombinant interleukin-2 (rIL-2)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4150,
      "start_date": "2000-03",
      "completion_date": "2008-11",
      "has_results": true,
      "last_update_posted_date": "2021-11-05",
      "last_synced_at": "2026-11-07T19:38:42.464Z",
      "location_count": 78,
      "location_summary": "Los Angeles, California • Mill Valley, California • Oakland, California + 33 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Mill Valley",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004978"
    },
    {
      "nct_id": "NCT01554956",
      "title": "Efficacy/Safety of Human Plasminogen Eye Drop in Ligneous Conjunctivitis Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Ligneous Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "Human Plasminogen",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Kedrion S.p.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 12,
      "start_date": "2013-05-22",
      "completion_date": "2020-12-04",
      "has_results": true,
      "last_update_posted_date": "2023-01-25",
      "last_synced_at": "2026-11-07T19:38:42.464Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01554956"
    },
    {
      "nct_id": "NCT00824005",
      "title": "Effectiveness of Stem Cell Treatment for Adults With Ischemic Cardiomyopathy (The FOCUS Study)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Ischemic Heart Disease",
        "Left Ventricular Dysfunction",
        "Angina",
        "Ischemic Cardiomyopathy"
      ],
      "interventions": [
        {
          "name": "Adult stem cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "The University of Texas Health Science Center, Houston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 92,
      "start_date": "2009-03",
      "completion_date": "2012-05",
      "has_results": true,
      "last_update_posted_date": "2015-07-01",
      "last_synced_at": "2026-11-07T19:38:42.464Z",
      "location_count": 5,
      "location_summary": "Gainesville, Florida • Minneapolis, Minnesota • Cleveland, Ohio + 2 more",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00824005"
    },
    {
      "nct_id": "NCT03344094",
      "title": "Mechanism of Action of Ocrelizumab in Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis",
        "Immune System Diseases"
      ],
      "interventions": [
        {
          "name": "ocrelizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 30,
      "start_date": "2018-02-23",
      "completion_date": "2019-04-10",
      "has_results": true,
      "last_update_posted_date": "2025-02-21",
      "last_synced_at": "2026-11-07T19:38:42.464Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03344094"
    },
    {
      "nct_id": "NCT01485341",
      "title": "Gluten Sensitivity in Non-Celiac Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Gluten Sensitivity"
      ],
      "interventions": [
        {
          "name": "gluten",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "rice starch",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of Campania Luigi Vanvitelli",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 108,
      "start_date": "2011-06",
      "completion_date": "2016-04",
      "has_results": false,
      "last_update_posted_date": "2016-04-13",
      "last_synced_at": "2026-11-07T19:38:42.464Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01485341"
    },
    {
      "nct_id": "NCT01262456",
      "title": "Investigation of the Superiority Effect of Orally Disintegrating Desmopressin Tablets to Placebo in Terms of Night Voids Reduction in Nocturia Adult Male Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Nocturia"
      ],
      "interventions": [
        {
          "name": "Desmopressin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ferring Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 395,
      "start_date": "2011-02",
      "completion_date": "2012-01",
      "has_results": true,
      "last_update_posted_date": "2015-10-15",
      "last_synced_at": "2026-11-07T19:38:42.464Z",
      "location_count": 51,
      "location_summary": "Anniston, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 45 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Foothill Rance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01262456"
    },
    {
      "nct_id": "NCT01865747",
      "title": "A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Cabozantinib tablets",
          "type": "DRUG"
        },
        {
          "name": "Everolimus (Afinitor) tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Exelixis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 658,
      "start_date": "2013-06",
      "completion_date": "2021-01-15",
      "has_results": true,
      "last_update_posted_date": "2021-04-27",
      "last_synced_at": "2026-11-07T19:38:42.464Z",
      "location_count": 59,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 46 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01865747"
    },
    {
      "nct_id": "NCT04207359",
      "title": "Effects of Creatine Supplementation in Breast Cancer Survivors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer",
        "Chemotherapy Effect",
        "Muscle Weakness",
        "Muscle Loss",
        "Exercise"
      ],
      "interventions": [
        {
          "name": "Creatine",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 75 Years · Female only"
      },
      "enrollment_count": 20,
      "start_date": "2020-09-30",
      "completion_date": "2023-03-07",
      "has_results": false,
      "last_update_posted_date": "2023-07-25",
      "last_synced_at": "2026-11-07T19:38:42.464Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04207359"
    },
    {
      "nct_id": "NCT03749096",
      "title": "Randomized Placebo Controlled Trial of IVIg in Glycine Receptor Antibody Positive Stiff-person Syndrome",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Stiff-Person Syndrome"
      ],
      "interventions": [
        {
          "name": "Intravenous Immunoglobulins, Human",
          "type": "DRUG"
        },
        {
          "name": "Placebos",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2018-12-07",
      "completion_date": "2019-04-26",
      "has_results": false,
      "last_update_posted_date": "2019-06-13",
      "last_synced_at": "2026-11-07T19:38:42.464Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03749096"
    }
  ]
}